查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2117969

智慧胰島素筆：市場洞察、競爭格局及市場預測 - 2034 年

Smart Insulin Pens - Market Insights, Competitive Landscape, and Market Forecast - 2034
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

概述：

  • 預計到 2025 年，智慧胰島素筆市場規模將達到 9.2 億美元，到 2034 年將達到 24.2 億美元。這一成長的促進因素包括：全球糖尿病負擔日益加重、患者和醫生越來越傾向於使用互聯的、數據驅動的胰島素輸注方式，以及智慧胰島素筆、持續血糖監測儀 (CGM) 和數位糖尿病管理平台之間日益緊密的整合。
  • 全球智慧胰島素筆市場預計在 2026 年至 2034 年的預測期內將以 11.4% 的複合年成長率成長。
  • 就連接方式而言，預計到 2025 年，支援藍牙連接的細分市場將佔 63% 的市場佔有率，引領智慧胰島素筆市場。
  • 就終端用戶而言，「醫院和診所」細分市場預計將引領智慧胰島素筆市場，到 2025 年將佔市場佔有率的 41%。
  • 按分銷管道分類，「醫院和零售藥局」預計將引領智慧胰島素筆市場，到 2025 年將佔 53% 的市場佔有率。
  • 預計到 2025 年，北美將佔 44% 的市場佔有率，推動全球智慧胰島素筆市場的銷售，並在全球取得最高的市場佔有率。

智慧胰島素筆是一種可重複使用或一次性使用的胰島素輸注裝置，或可連接到傳統胰島素筆的智慧附件。它能自動記錄每次注射的劑量、日期和時間，並透過藍牙、NFC、USB 或雲端連接將這些資訊傳輸到相容的行動應用程式。透過數位化胰島素給藥，這些設備支援劑量追蹤、漏服提醒、大劑量投藥劑量計算、體內剩餘胰島素水平估算以及與持續血糖監測儀的整合，從而幫助糖尿病患者和醫護人員做出更明智、更基於數據的治療決策。根據連接方式，市場可細分為藍牙連接型、NFC 連接型、USB 連接型和無線/雲端連接型胰島素筆。終端使用者包括醫院和診所、居家照護機構、糖尿病專科中心和門診中心，而分銷管道包括醫院、零售藥局、糖尿病診所和中心以及電子商務平台。在全球糖尿病患者數量激增、對個人化數位糖尿病管理的需求不斷成長以及設備和應用程式之間、設備和連續血糖監測儀 (CGM) 之間的連接日益加速的推動下，智慧胰島素筆在互聯糖尿病護理生態系統中變得越來越重要。

智慧胰島素筆市場的主要促進因素

  • 隨著全球糖尿病負擔加重，患者群體也不斷擴大。根據國際糖尿病聯盟（IDF）估計，到2024年，全球將有5.89億成年人患有糖尿病，預計到2050年，這一數字將達到8.53億。
  • 與傳統胰島素筆相比，醫生和患者越來越傾向於使用連網胰島素輸注系統，加速了其普及。這是因為自動記錄劑量可以減少漏服和重複給藥，從而提高治療依從性。
  • 智慧胰島素筆與持續血糖監測系統的整合正在不斷擴展。例如，Medtronic的「InPen」胰島素筆與德康醫療和FreeStyle Libre血糖儀的感測器相容，為每天多次注射胰島素的患者提供了數據豐富、近乎閉合迴路管理體驗。
  • 諾和諾德、賽諾菲和禮來等領先的胰島素生產商正在將連接功能直接整合到其胰島素輸送生態系統中，以鼓勵患者留存並支持基於價值的醫療保健合約。
  • 智慧型手機普及率的不斷提高和糖尿病管理應用程式數量的不斷成長降低了採用連網筆的門檻，尤其是在居家照護和門診環境中。
  • 在美國和歐洲部分地區，針對連網胰島素輸送設備的優惠報銷方案和擴大保險覆蓋範圍正在製定中，這將提高胰島素的可負擔性和處方量。
  • 併購和授權活動日益頻繁，例如雅培收購Bigfoot Biomedical和諾和諾德收購Biocorp。這加速了智慧筆技術在大規模糖尿病照護和製藥平台中​​的整合和商業化。

推動智慧胰島素筆市場成長的因素

市場促進因素

全球糖尿病負擔日益加重，胰島素依賴型患者人數不斷增加。

智慧胰島素筆市場最大的驅動力是全球糖尿病患者數量龐大且持續成長。根據國際糖尿病聯盟 (IDF) 估計，到 2024 年，全球將有 5.89 億成年人患有糖尿病，約佔全球成年人口的九分之一。預計到 2050 年，這一數字將達到 8.53 億。在這部分患者族群中，包括需要使用胰島素治療的 1 型糖尿病和 2 型糖尿病患者，很大一部分依賴於每天多次使用胰島素筆進行注射，這推動了智慧胰島素筆技術用戶群的龐大且持續成長。隨著已開發市場和新興市場接受胰島素治療的患者人數不斷增加，以及臨床醫生對客觀劑量數據的需求日益成長以指導治療方案的改進，能夠自動記錄和傳輸劑量信息的智慧胰島素筆的需求也將相應成長，從而推動市場在 2034 年前持續成長。

對個人化、數據驅動型糖尿病管理的需求日益成長

智慧胰島素筆解決了糖尿病照護中長期存在的一個難題：缺乏與血糖值監測儀提供的客觀、即時的胰島素給藥數據相媲美的數據。這些設備能夠自動記錄每次注射的劑量和時間，無需手寫記錄，減少漏服和重複注射，並使患者和醫護人員能夠結合血糖值趨勢回顧注射歷史。這項功能可實現更個人化的劑量調整，更準確地識別出漏服基礎胰島素等模式，並提高臨床效率。隨著保險公司和醫療機構越來越重視以價值為導向、以數據為驅動的糖尿病護理，1 型和 2 型糖尿病患者對智慧胰島素筆提供的客觀給藥記錄的需求持續成長。

市場限制因素

儘管基礎穩固，智慧胰島素筆市場仍面臨諸多限制。與傳統胰島素筆相比，智慧胰島素筆及其配套的附加元件筆蓋的初始成本和單價較高，這仍然是其普及推廣的障礙，尤其是在對價格敏感、自付醫療費用較高的新興市場。不同地區對智慧胰島素輸注設備的保險報銷政策不盡相同，即使臨床療效已得到充分證實，患者仍需承擔部分費用，這阻礙了智慧胰島素筆的廣泛應用。此外，傳輸和儲存個人健康及用藥資訊所涉及的資料隱私和網路安全問題也令部分病患和醫療服務提供者望而卻步。不同廠商生產的胰島素筆、應用程式和持續血糖監測（CGM）系統之間的互通性問題也可能導致使用者體驗不佳，並使臨床工作流程複雜化。中低收入地區患者，甚至部分醫療服務提供者對智慧胰島素筆技術的認知度較低，也阻礙了其在成熟市場以外的推廣應用；而依賴智慧型手機配對則使得那些無法穩定使用智慧型手機的患者無法使用智慧型胰島素筆。禮來公司決定於2026年停止Tempo個人化糖尿病管理平台，凸顯了商業性和報銷方面的不確定性，即使是資金充足的智慧胰島素筆計畫也可能受到影響。儘管糖尿病盛行率持續上升以及數位醫療的廣泛應用是推動其發展的根本因素，但由於成本、報銷、資料安全、互通性和認知度低等諸多障礙，數位醫療的普及速度正在放緩。

目錄

第1章：智慧胰島素筆市場：引言

  • 調查範圍
  • 市場區隔
  • 市場先決條件

第2章：智慧型胰島素筆市場：摘要整理

  • 市場概覽

第3章：智慧型胰島素筆市場：關鍵因素分析

  • 智慧胰島素筆市場：市場促進因素
    • 全球糖尿病負擔日益加重
    • 對個人化、數據驅動型糖尿病管理的需求
    • 與連續血糖監測系統整合
    • 胰島素生產商的戰略投資
  • 智慧胰島素筆市場：限制因素與挑戰
    • 設備成本與保險賠償不一致
    • 對資料隱私和互通性的擔憂
    • 新興市場的認知差距
  • 智慧胰島素筆市場：市場機遇
    • 擴展 CGM 和閉合迴路決策支援系統
    • 透過新興市場實現成長並改造為智慧帽

第4章：人工智慧、地緣政治、貿易與經濟趨勢

第5章：監理分析

  • 美國
  • 歐洲
  • 日本
  • 中國

第6章：波特五力分析

第7章：智慧型胰島素筆市場：評估

  • 按連線類型
    • 藍牙相容
    • 相容NFC
    • USB連接類型
    • 無線/雲端連接
  • 最終用戶
    • 醫院和診所
    • 居家照護環境
    • 糖尿病專科中心
    • 門診部
    • 其他
  • 透過分銷管道
    • 醫院和零售藥局
    • 糖尿病診所中心
    • 電子商務
  • 按地區
    • 北美洲
    • 歐洲
    • 亞太地區
    • 世界其他地區

第8章：智慧胰島素筆市場：競爭格局

  • 市場集中度與結構
  • 競爭定位與市場佔有率分析（加值服務）

第9章：智慧胰島素筆市場：新創企業資金籌措與投資趨勢

第10章：智慧胰島素筆市場：公司概況與產品概況

  • Emperra GmbH E-Health Technologies
  • Jiangsu Delfu Medical Device Co., Ltd.
  • Medtronic
  • Novo Nordisk A/S
  • Pendiq
  • Sanofi
  • Berlin-Chemie
  • Bigfoot Biomedical
  • Digital Medics Pty Ltd.
  • Eli Lilly

第11章：KOL的觀點

第12章：專案式教學方法

第13章：關於 DelveInsight

第14章 免責聲明與聯絡方式

Product Code: DIMDCL0442

Smart Insulin Pens Market Summary

Overview:

  • The Smart Insulin Pens market is estimated at USD 0.92 billion in 2025 and is projected to reach USD 2.42 billion by 2034. Growth is anchored in the rising global burden of diabetes, growing patient and physician preference for connected, data-driven insulin delivery, and expanding integration between smart pens, continuous glucose monitors (CGMs), and digital diabetes-management platforms.
  • The global Smart Insulin Pens market is growing at a CAGR of 11.4% during the forecast period from 2026 to 2034.
  • By connectivity type, the Bluetooth-Enabled segment dominated the Smart Insulin Pens market with a 63% share in 2025.
  • By end-user, the Hospitals & Clinics segment dominated the Smart Insulin Pens market with a 41% share in 2025.
  • By distribution channel, the Hospital & Retail Pharmacy segment dominated the Smart Insulin Pens market with a 53% share in 2025.
  • North America dominated the global Smart Insulin Pens market revenue with a 44% share in 2025, representing the highest regional market share globally.

A smart insulin pen is a reusable or disposable insulin delivery device, or a connected add-on cap for a conventional pen, that automatically captures the dose, date, and time of each injection and transmits this information via Bluetooth, NFC, USB, or cloud connectivity to a companion mobile application. By digitizing insulin dosing, these devices support dose-tracking, missed-dose alerts, bolus calculation, insulin-on-board estimation, and integration with continuous glucose monitors, helping people with diabetes and their clinicians make more informed, data-backed treatment decisions. The market is organized by connectivity type across Bluetooth-enabled, NFC-enabled, USB-connected, and wireless/cloud-connected pens; by end-user, spanning hospitals and clinics, homecare settings, diabetes specialty centers, and ambulatory care centers; and by distribution channel, including hospital and retail pharmacies, diabetic clinics and centers, and e-commerce. Driven by the surging global diabetes population, rising demand for personalized digital diabetes management, and accelerating device-to-app and device-to-CGM connectivity, smart insulin pens are becoming an increasingly central component of the connected diabetes-care ecosystem.

Smart Insulin Pens Market Key Growth Drivers

  • The rising global burden of diabetes is expanding the addressable patient population, with the International Diabetes Federation estimating 589 million adults living with diabetes in 2024, a figure projected to reach 853 million by 2050.
  • Growing physician and patient preference for connected insulin delivery over conventional pens is accelerating adoption, as automatic dose-logging reduces missed or duplicated doses and improves treatment adherence.
  • Expanding integration between smart insulin pens and continuous glucose monitoring systems, such as Medtronic InPen's compatibility with Dexcom and FreeStyle Libre sensors, is creating a data-rich, near-closed-loop management experience for people on multiple daily injections.
  • Major insulin manufacturers, including Novo Nordisk, Sanofi, and Eli Lilly, are embedding connectivity directly into their branded insulin delivery ecosystems to strengthen patient retention and support value-based care contracting.
  • Rising smartphone penetration and the proliferation of diabetes-management apps are lowering the adoption barrier for connected pens, particularly in homecare and ambulatory settings.
  • Favorable reimbursement developments and expanding insurance coverage for connected insulin delivery devices in the United States and parts of Europe are improving affordability and prescription volumes.
  • Growing merger, acquisition, and licensing activity, including Abbott's acquisition of Bigfoot Biomedical and Novo Nordisk's acquisition of Biocorp, is consolidating smart-pen technology within larger diabetes-care and pharmaceutical platforms and accelerating commercialization.

Key Companies in Smart Insulin Pens Market

The competitive landscape is led by the following active manufacturers:

  • Emperra GmbH E-Health Technologies
  • Jiangsu Delfu Medical Device Co., Ltd.
  • Medtronic
  • Novo Nordisk A/S
  • Pendiq
  • Sanofi
  • Berlin-Chemie
  • Bigfoot Biomedical
  • Digital Medics Pty Ltd.
  • Eli Lilly and Company

Factors Contributing to the Growth of the Smart Insulin Pens Market

Market Drivers

Rising Global Diabetes Burden and Insulin-Dependent Population

The single most powerful driver of the Smart Insulin Pens market is the sheer scale and continued growth of the global diabetes population. The International Diabetes Federation estimates that 589 million adults were living with diabetes in 2024, equivalent to roughly one in nine adults worldwide, with the figure projected to rise to 853 million by 2050. A substantial share of this population, spanning both type 1 diabetes and insulin-requiring type 2 diabetes, relies on multiple daily insulin injections delivered by pen, creating a large and expanding installed base for connected pen technology. As insulin-treated populations grow across both developed and emerging markets, and as clinicians increasingly seek objective dosing data to guide therapy intensification, demand for smart insulin pens that automatically capture and transmit dosing information expands in step, anchoring market growth through 2034.

Growing Demand for Personalized, Data-Driven Diabetes Management

Smart insulin pens address a long-standing gap in diabetes care: the absence of objective, real-time insulin dosing data comparable to what continuous glucose monitors already provide for glucose levels. By automatically logging the size and timing of every injection, these devices eliminate manual dose diaries, reduce missed or duplicated doses, and allow both patients and healthcare providers to review injection history alongside glucose trends. This capability supports more personalized dose titration, better identification of patterns such as skipped basal doses, and more productive clinic visits. As payers and providers increasingly emphasize value-based, data-informed diabetes care, demand for the objective dosing record that smart pens provide continues to strengthen across both type 1 and type 2 diabetes populations.

Market Restraints

Despite strong underlying momentum, the Smart Insulin Pens market faces material constraints. The higher upfront and per-unit cost of smart pens and connected add-on caps relative to conventional insulin pens remains a barrier to adoption, particularly in price-sensitive and emerging markets where out-of-pocket healthcare spending is high. Reimbursement for connected insulin delivery devices remains inconsistent across geographies, and coverage gaps can leave patients responsible for costs that limit uptake even where clinical benefit is well established. Data privacy and cybersecurity concerns associated with the transmission and storage of personal health and dosing information create hesitancy among some patients and providers, and interoperability challenges between different manufacturers' pens, apps, and CGM systems can fragment the user experience and complicate clinical workflows. Limited awareness of smart-pen technology among patients and even some healthcare providers in low- and middle-income regions constrains penetration outside established markets, and reliance on smartphone pairing excludes patients without consistent smartphone access. Eli Lilly's 2026 decision to discontinue its Tempo Personalized Diabetes Management Platform underscores the commercial and reimbursement uncertainty that can affect even well-resourced connected-pen programs. Together, these cost, reimbursement, data-security, interoperability, and awareness barriers temper the pace of adoption, even as the underlying drivers of rising diabetes prevalence and digital health adoption remain firmly intact.

Smart Insulin Pens Market Segment Analysis

The smart insulin pens market by connectivity type (bluetooth-enabled, nfc-enabled, usb-connected, wireless/cloud-connected), end-users (hospitals & clinics, homecare settings, diabetes specialty centers, ambulatory care centers, others), distribution channels (hospital & retail pharmacy, diabetic clinics & centers, e-commerce, others), and geography (North America, Europe, Asia-Pacific, and Rest of World).

By Connectivity Type

Dominant Subsegment: Bluetooth-Enabled.

The Bluetooth-enabled segment accounted for 63% of the Smart Insulin Pens market in 2025. Bluetooth-enabled pens are the leading connectivity type because Bluetooth Low Energy offers reliable, low-power, continuous pairing with smartphones, enabling automatic, real-time transfer of dosing data without requiring the patient to actively tap or scan the device. Leading products such as Medtronic's InPen, Novo Nordisk's NovoPen 6 and NovoPen Echo Plus, and Eli Lilly's Tempo Smart Button all rely on Bluetooth connectivity, giving the segment the deepest catalog of commercially available, clinically validated devices. Bluetooth's broad compatibility with both iOS and Android diabetes-management apps, together with its established role in CGM data transmission, makes it the natural default for manufacturers building integrated glucose-and-insulin data platforms. While NFC-enabled pens are the fastest-growing connectivity type, valued for their simplicity and lower power requirements in markets such as Germany where Emperra's ESYSTA pioneered Bluetooth-enabled dosing, the breadth of Bluetooth's device ecosystem and its central role in CGM integration secure the segment's leadership across the forecast period.

By End-Users

Dominant Subsegment: Hospitals & Clinics.

The hospitals & clinics segment accounted for 41% of the Smart Insulin Pens market in 2025. Hospitals and clinics are the leading end-user category because they serve as the primary point of diabetes diagnosis, insulin therapy initiation, and device prescription, giving endocrinologists and diabetes educators direct influence over which connected pens patients adopt. Clinical settings also generate the greatest immediate value from objective dosing data, since physicians use pen-generated injection histories to titrate therapy, identify adherence gaps, and support insurance documentation during in-person visits. Hospitals and specialty diabetes clinics were also the first sites to pilot smart-pen programs such as the Bigfoot Unity Program, reinforcing clinical familiarity and referral pathways. While homecare settings are the fastest-growing end-user category as more patients self-manage therapy at home with continuous app-based support, the central role of hospitals and clinics in device prescription and therapy titration secures the segment's leadership across the forecast period.

Smart Insulin Pens Market Region Analysis

Dominant Region: North America

North America accounted for 44% of the global Smart Insulin Pens market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects a high prevalence of diagnosed diabetes, strong insurance and reimbursement coverage for connected insulin delivery devices, and the presence of leading manufacturers including Medtronic, Eli Lilly, and Abbott (following its acquisition of Bigfoot Biomedical). The United States in particular benefits from broad adoption of the InPen and Bigfoot Unity systems, extensive CGM penetration that creates natural pull-through demand for CGM-compatible smart pens, and FDA clearance pathways that have supported a steady stream of new connected-device launches. Strong direct-to-consumer digital health marketing, employer and payer-sponsored diabetes management programs, and deep integration with popular diabetes apps further reinforce the region's leadership across the forecast period.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is the fastest-growing region in the Smart Insulin Pens market. The region's elevated CAGR is driven by its enormous and rapidly growing diabetic population, led by China and India, alongside rising healthcare expenditure, expanding private insurance coverage, and growing local manufacturing capability. China's Jiangsu Delfu Medical Device Co., Ltd. is scaling domestic production of connected insulin delivery devices, Japan is seeing steady adoption of digital diabetes-management tools within its advanced healthcare system, and India's large and increasingly urban diabetic population is driving demand for affordable connected pens and smart-cap add-ons. Government initiatives to modernize chronic-disease management and growing awareness of digital health tools among both patients and physicians are accelerating adoption, positioning Asia-Pacific as the principal source of incremental market growth over the forecast period.

Regional Commentary

North America

North America accounted for 44% of the global Smart Insulin Pens market revenue in 2025. The United States dominates on the strength of its high diagnosed-diabetes prevalence, favorable device reimbursement, deep CGM penetration, and the concentration of leading manufacturers including Medtronic, Eli Lilly, and Abbott, while Canada contributes steady growth supported by its public healthcare system's gradual expansion of connected-device coverage.

Europe

Europe is a large and technologically advanced regional market, anchored by Germany, home to Emperra GmbH E-Health Technologies, whose ESYSTA pen was among the first Bluetooth-enabled smart insulin pens to receive European Commission approval, and Pendiq, another German developer of connected insulin delivery devices. Berlin-Chemie and Sanofi's SoloSmart, developed with Biocorp, extend the region's connected-pen footprint across Germany, France, the United Kingdom, Italy, and Spain, supported by established EU medical device regulatory frameworks and growing statutory health-insurance coverage for digital diabetes tools.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by its large and expanding diabetic population across China, Japan, India, South Korea, and Australia. China's Jiangsu Delfu Medical Device Co., Ltd. is expanding domestic manufacturing and distribution of connected insulin pens, Japan's advanced healthcare infrastructure supports steady premium-device adoption, and India's growing private healthcare and insurance sector is broadening access to smart insulin delivery technology, together accelerating regional market growth.

Rest of World

The Rest of World region, spanning Latin America, the Middle East, and Africa, is an emerging growth frontier for smart insulin pens. Rising diabetes prevalence, gradually improving healthcare infrastructure, and growing awareness of digital diabetes-management tools, led by companies such as Digital Medics Pty Ltd., extending connectivity solutions into new markets, are broadening access, while international distribution partnerships and expanding private insurance coverage support the gradual build-out of regional demand.

Smart Insulin Pens Market Competitive Landscape

The Smart Insulin Pens market is classified as Moderately Fragmented. A group of large, diversified medical device and pharmaceutical companies with global distribution, including Medtronic, Novo Nordisk A/S, Sanofi, and Eli Lilly and Company, anchor the top tier by embedding connectivity into branded insulin ecosystems, while specialized connected-device developers such as Emperra GmbH E-Health Technologies, Pendiq, Berlin-Chemie, Bigfoot Biomedical, Jiangsu Delfu Medical Device Co., Ltd., and Digital Medics Pty Ltd. compete through focused smart-cap and smart-pen innovation, regional manufacturing strength, and niche connectivity partnerships.

The competitive landscape can be evaluated across the following dimensions:

  • Market concentration: Moderately fragmented, with large insulin and device manufacturers leading distribution scale alongside specialized connected-pen innovators.
  • Leading players: Medtronic, Novo Nordisk A/S, Sanofi, and Eli Lilly and Company anchor the top tier through branded insulin ecosystem integration and global reach.
  • Geographic reach: Leaders operate global distribution networks, while regional specialists such as Emperra, Pendiq, and Berlin-Chemie maintain strong footholds in the German and broader European market.
  • Product portfolio strength: Top players offer integrated pen-plus-app-plus-CGM ecosystems spanning dose logging, bolus calculation, and insulin-on-board tracking.
  • Connectivity technology: Ownership of validated Bluetooth, NFC, and cloud-connectivity platforms, together with CGM interoperability, is a decisive competitive advantage.
  • Strategic partnerships: Tie-ups between insulin manufacturers and device or app developers, such as Sanofi and Biocorp's SoloSmart and Medtronic InPen's Dexcom and FreeStyle Libre integrations, extend ecosystem reach.
  • M&A activity: Active consolidation, including Abbott's acquisition of Bigfoot Biomedical and Novo Nordisk's acquisition of Biocorp, is concentrating connected-pen technology within larger diabetes-care platforms.
  • Manufacturing capabilities: Precision dose-sensing electronics, miniaturized Bluetooth and NFC modules, and regulatory-grade quality manufacturing are key competitive moats.
  • Innovation focus: CGM integration, AI-assisted dose guidance, expanded smartphone and wearable compatibility, and next-generation smart-cap retrofits for disposable pens.

Smart Insulin Pens Market Recent Developmental Activities

In 2026, Eli Lilly and Company announced the discontinuation of its Tempo Personalized Diabetes Management Platform, including the Tempo Smart Button, Tempo Pens, and TempoSmart app, by the end of 2026, shifting affected patients toward standard KwikPen insulin delivery and the Lilly Insulin Value Savings Card. Strategic significance: Signals the commercial and reimbursement challenges connected-pen programs can face even when backed by a major insulin manufacturer.

Smart Insulin Pens Market Segmentation

Smart Insulin Pens Market by Connectivity Type

  • Bluetooth-Enabled
  • NFC-Enabled
  • USB-Connected
  • Wireless/Cloud-Connected

Smart Insulin Pens Market by End-Users

  • Hospitals & Clinics
  • Homecare Settings
  • Diabetes Specialty Centers
  • Ambulatory Care Centers
  • Others

Smart Insulin Pens Market by Distribution Channels

  • Hospital & Retail Pharmacy
  • Diabetic Clinics & Centers
  • E-commerce
  • Others

Smart Insulin Pens Market by Geography

  • North America Smart Insulin Pens Market
  • United States Smart Insulin Pens Market Size in USD million (2023-2034)
  • Canada Smart Insulin Pens Market Size in USD million (2023-2034)
  • Mexico Smart Insulin Pens Market Size in USD million (2023-2034)
  • Europe Smart Insulin Pens Market
  • Germany Smart Insulin Pens Market Size in USD million (2023-2034)
  • United Kingdom Smart Insulin Pens Market Size in USD million (2023-2034)
  • France Smart Insulin Pens Market Size in USD million (2023-2034)
  • Italy Smart Insulin Pens Market Size in USD million (2023-2034)
  • Spain Smart Insulin Pens Market Size in USD million (2023-2034)
  • Rest of Europe Smart Insulin Pens Market Size in USD million (2023-2034)
  • Asia-Pacific Smart Insulin Pens Market
  • China Smart Insulin Pens Market Size in USD million (2023-2034)
  • Japan Smart Insulin Pens Market Size in USD million (2023-2034)
  • India Smart Insulin Pens Market Size in USD million (2023-2034)
  • Australia Smart Insulin Pens Market Size in USD million (2023-2034)
  • South Korea Smart Insulin Pens Market Size in USD million (2023-2034)
  • Rest of Asia-Pacific Smart Insulin Pens Market Size in USD million (2023-2034)
  • Rest of the World (RoW) Smart Insulin Pens Market
  • Middle East Smart Insulin Pens Market Size in USD million (2023-2034)
  • Africa Smart Insulin Pens Market Size in USD million (2023-2034)
  • South America Smart Insulin Pens Market Size in USD million (2023-2034)

Key Takeaways from the Smart Insulin Pens Market Report Study

  • Market size analysis for the current Smart Insulin Pens market size (2025), and market forecast for 9 years (2026 to 2034).
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
  • Key companies dominating the global Smart Insulin Pens market.
  • Various opportunities available for competitors in the Smart Insulin Pens market space.
  • What are the top-performing segments in 2025? How will these segments perform in 2034?
  • Which are the top-performing regions and countries in the current Smart Insulin Pens market scenario?
  • Which are the regions and countries where companies should concentrate their opportunities for Smart Insulin Pens market growth in the future?

Target audience who can benefit from this Smart Insulin Pens market report study

  • Smart Insulin Pens product providers
  • Research organizations and consulting companies
  • Smart Insulin Pens therapeutics-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in Smart Insulin Pens
  • Various end-users who want to know more about the Smart Insulin Pens market and the latest technological developments in the Smart Insulin Pens market.

Frequently Asked Questions:

Q1. What is the growth rate of the Smart Insulin Pens market?

The Smart Insulin Pens market is projected to expand at a CAGR of 11.4% during the forecast period from 2026-2034.

Q2. What is the market size of the Smart Insulin Pens market?

The Smart Insulin Pens market is estimated at USD 0.92 billion in 2025 and is projected to reach USD 2.42 billion by 2034.

Q3. Which region dominates the Smart Insulin Pens market?

North America dominated the Smart Insulin Pens market with a 44% share of global revenue in 2025, supported by high diagnosed diabetes prevalence, favorable reimbursement, deep CGM penetration, and the concentration of leading manufacturers including Medtronic, Eli Lilly, and Abbott. Asia-Pacific is the fastest-growing region over the forecast period.

Q4. What are the key drivers of the Smart Insulin Pens market?

The principal drivers are the rising global burden of diabetes, with the International Diabetes Federation estimating 589 million adults living with diabetes in 2024 and projecting 853 million by 2050; growing demand for personalized, data-driven diabetes management; expanding integration between smart pens and continuous glucose monitoring systems; strategic investment by major insulin manufacturers; rising smartphone and digital health app penetration; and accelerating consolidation and M&A activity.

Q5. Who are the major players in the Smart Insulin Pens market?

The major players include Emperra GmbH E-Health Technologies, Jiangsu Delfu Medical Device Co., Ltd., Medtronic, Novo Nordisk A/S, Pendiq, Sanofi, Berlin-Chemie, Bigfoot Biomedical, Digital Medics Pty Ltd., and Eli Lilly and Company, among other active providers profiled in the Competitive Landscape section. Medtronic, Novo Nordisk A/S, Sanofi, and Eli Lilly and Company lead through branded insulin ecosystem integration and global distribution reach.

Table of Contents

1. Smart Insulin Pens Market Report Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Segmentation
  • 1.3 Market Assumptions

2. Smart Insulin Pens Market Executive Summary

  • 2.1 Market at a Glance

3. Smart Insulin Pens Market Key Factors Analysis

  • 3.1 Smart Insulin Pens Market Drivers
    • 3.1.1 Rising Global Diabetes Burden
    • 3.1.2 Demand for Personalized, Data-Driven Diabetes Management
    • 3.1.3 Integration with Continuous Glucose Monitoring Systems
    • 3.1.4 Strategic Investment by Insulin Manufacturers
  • 3.2 Smart Insulin Pens Market Restraints and Challenges
    • 3.2.1 Device Cost and Reimbursement Inconsistency
    • 3.2.2 Data Privacy and Interoperability Concerns
    • 3.2.3 Awareness Gaps in Emerging Markets
  • 3.3 Smart Insulin Pens Market Opportunities
    • 3.3.1 CGM and Closed-Loop Decision Support Expansion
    • 3.3.2 Emerging-Market and Smart-Cap Retrofit Growth

4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments

5. Regulatory Analysis

  • 5.1 United States
  • 5.2 Europe
  • 5.3 Japan
  • 5.4 China

6. Smart Insulin Pens Market Porter's Five Forces Analysis

  • 6.1 Bargaining Power of Suppliers
  • 6.2 Bargaining Power of Buyers
  • 6.3 Threat of New Entrants
  • 6.4 Threat of Substitutes
  • 6.5 Competitive Rivalry

7. Smart Insulin Pens Market Assessment

  • 7.1 By Connectivity Type
    • 7.1.1 Bluetooth-Enabled
    • 7.1.2 NFC-Enabled
    • 7.1.3 USB-Connected
    • 7.1.4 Wireless/Cloud-Connected
  • 7.2 By End-Users
    • 7.2.1 Hospitals & Clinics
    • 7.2.2 Homecare Settings
    • 7.2.3 Diabetes Specialty Centers
    • 7.2.4 Ambulatory Care Centers
    • 7.2.5 Others
  • 7.3 By Distribution Channels
    • 7.3.1 Hospital & Retail Pharmacy
    • 7.3.2 Diabetic Clinics & Centers
    • 7.3.3 E-commerce
    • 7.3.4 Others
  • 7.4 By Geography
    • 7.4.1 North America
      • 7.4.1.1 United States Smart Insulin Pens Market Size in USD million (2023-2034)
      • 7.4.1.2 Canada Smart Insulin Pens Market Size in USD million (2023-2034)
      • 7.4.1.3 Mexico Smart Insulin Pens Market Size in USD million (2023-2034)
    • 7.4.2 Europe
      • 7.4.2.1 Germany Smart Insulin Pens Market Size in USD million (2023-2034)
      • 7.4.2.2 United Kingdom Smart Insulin Pens Market Size in USD million (2023-2034)
      • 7.4.2.3 France Smart Insulin Pens Market Size in USD million (2023-2034)
      • 7.4.2.4 Italy Smart Insulin Pens Market Size in USD million (2023-2034)
      • 7.4.2.5 Spain Smart Insulin Pens Market Size in USD million (2023-2034)
      • 7.4.2.6 Rest of Europe Smart Insulin Pens Market Size in USD million (2023-2034)
    • 7.4.3 Asia-Pacific
      • 7.4.3.1 China Smart Insulin Pens Market Size in USD million (2023-2034)
      • 7.4.3.2 Japan Smart Insulin Pens Market Size in USD million (2023-2034)
      • 7.4.3.3 India Smart Insulin Pens Market Size in USD million (2023-2034)
      • 7.4.3.4 Australia Smart Insulin Pens Market Size in USD million (2023-2034)
      • 7.4.3.5 South Korea Smart Insulin Pens Market Size in USD million (2023-2034)
      • 7.4.3.6 Rest of Asia-Pacific Smart Insulin Pens Market Size in USD million (2023-2034)
    • 7.4.4 Rest of World
      • 7.4.4.1 Middle East Smart Insulin Pens Market Size in USD million (2023-2034)
      • 7.4.4.2 Africa Smart Insulin Pens Market Size in USD million (2023-2034)
      • 7.4.4.3 South America Smart Insulin Pens Market Size in USD million (2023-2034)

8. Smart Insulin Pens Market Competitive Landscape

  • 8.1 Market Concentration and Structure
  • 8.2 Competitive Positioning and Market Share Analysis (Premium Offering)

9. Smart Insulin Pens Market Startup Funding and Investment Trends

10. Smart Insulin Pens Market Company and Product Profiles

  • 10.1 Emperra GmbH E-Health Technologies
    • 10.1.1 Company Overview
    • 10.1.2 Company Snapshot
    • 10.1.3 Financial Overview
    • 10.1.4 Service Portfolio
    • 10.1.5 Strategic Initiatives / Entropy
  • 10.2 Jiangsu Delfu Medical Device Co., Ltd.
    • 10.2.1 Company Overview
    • 10.2.2 Company Snapshot
    • 10.2.3 Financial Overview
    • 10.2.4 Product Portfolio
    • 10.2.5 Strategic Initiatives / Entropy
  • 10.3 Medtronic
    • 10.3.1 Company Overview
    • 10.3.2 Company Snapshot
    • 10.3.3 Financial Overview
    • 10.3.4 Product Portfolio
    • 10.3.5 Strategic Initiatives / Entropy
  • 10.4 Novo Nordisk A/S
    • 10.4.1 Company Overview
    • 10.4.2 Company Snapshot
    • 10.4.3 Financial Overview
    • 10.4.4 Product Portfolio
    • 10.4.5 Strategic Initiatives / Entropy
  • 10.5 Pendiq
    • 10.5.1 Company Overview
    • 10.5.2 Company Snapshot
    • 10.5.3 Financial Overview
    • 10.5.4 Product Portfolio
    • 10.5.5 Strategic Initiatives / Entropy
  • 10.6 Sanofi
    • 10.6.1 Company Overview
    • 10.6.2 Company Snapshot
    • 10.6.3 Financial Overview
    • 10.6.4 Product Portfolio
    • 10.6.5 Strategic Initiatives / Entropy
  • 10.7 Berlin-Chemie
    • 10.7.1 Company Overview
    • 10.7.2 Company Snapshot
    • 10.7.3 Financial Overview
    • 10.7.4 Product Portfolio
    • 10.7.5 Strategic Initiatives / Entropy
  • 10.8 Bigfoot Biomedical
    • 10.8.1 Company Overview
    • 10.8.2 Company Snapshot
    • 10.8.3 Financial Overview
    • 10.8.4 Product Portfolio
    • 10.8.5 Strategic Initiatives / Entropy
  • 10.9 Digital Medics Pty Ltd.
    • 10.9.1 Company Overview
    • 10.9.2 Company Snapshot
    • 10.9.3 Financial Overview
    • 10.9.4 Product Portfolio
    • 10.9.5 Strategic Initiatives / Entropy

10. Eli Lilly and Company

    • 10.10.1 Company Overview
    • 10.10.2 Company Snapshot
    • 10.10.3 Financial Overview
    • 10.10.4 Product Portfolio
    • 10.10.5 Strategic Initiatives / Entropy

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer and Contact Us

List of Tables

  • Table 1: Smart Insulin Pens Market in Global (2023-2034)
  • Table 2: Smart Insulin Pens Market in Global by Connectivity Type (2023-2034)
  • Table 3: Smart Insulin Pens Market in Global by End-Users (2023-2034)
  • Table 4: Smart Insulin Pens Market in Global by Distribution Channel (2023-2034)
  • Table 5: Smart Insulin Pens Market in Global by Geography (2023-2034)
  • Table 6: Smart Insulin Pens Market in North America (2023-2034)
  • Table 7: Smart Insulin Pens Market in the United States (2023-2034)
  • Table 8: Smart Insulin Pens Market in Canada (2023-2034)
  • Table 9: Smart Insulin Pens Market in Mexico (2023-2034)
  • Table 10: Smart Insulin Pens Market in Europe (2023-2034)
  • Table 11: Smart Insulin Pens Market in Germany (2023-2034)
  • Table 12: Smart Insulin Pens Market in United Kingdom (2023-2034)
  • Table 13: Smart Insulin Pens Market in France (2023-2034)
  • Table 14: Smart Insulin Pens Market in Italy (2023-2034)
  • Table 15: Smart Insulin Pens Market in Spain (2023-2034)
  • Table 16: Smart Insulin Pens Market in the Rest of Europe (2023-2034)
  • Table 17: Smart Insulin Pens Market in Asia-Pacific (2023-2034)
  • Table 18: Smart Insulin Pens Market in China (2023-2034)
  • Table 19: Smart Insulin Pens Market in Japan (2023-2034)
  • Table 20: Smart Insulin Pens Market in India (2023-2034)
  • Table 21: Smart Insulin Pens Market in Australia (2023-2034)
  • Table 22: Smart Insulin Pens Market in South Korea (2023-2034)
  • Table 23: Smart Insulin Pens Market in Rest of Asia-Pacific (2023-2034)
  • Table 24: Smart Insulin Pens Market in the Rest of the World (2023-2034)
  • Table 25: Smart Insulin Pens Market in the Middle East (2023-2034)
  • Table 26: Smart Insulin Pens Market in Africa (2023-2034)
  • Table 27: Smart Insulin Pens Market in South America (2023-2034)
  • Table 28: Competitive Landscape
  • Table 29: Startup Funding and Investment Trends

List of Figures

  • Figure 1: Smart Insulin Pens Market Drivers
  • Figure 2: Smart Insulin Pens Market Restraints
  • Figure 3: Smart Insulin Pens Market Opportunities
  • Figure 4: Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
  • Figure 5: Regulatory Analysis (US, EU, Japan, China)
  • Figure 6: Porter's Five Forces Analysis
  • Figure 7: Competitive Analysis
  • Figure 8: Smart Insulin Pens Market in Global (2023-2034)
  • Figure 9: Smart Insulin Pens Market in Global by Connectivity Type (2023-2034)
  • Figure 10: Smart Insulin Pens Market in Global by End-Users (2023-2034)
  • Figure 11: Smart Insulin Pens Market in Global by Distribution Channel (2023-2034)
  • Figure 12: Smart Insulin Pens Market in Global by Geography (2023-2034)
  • Figure 13: Smart Insulin Pens Market in North America (2023-2034)
  • Figure 14: Smart Insulin Pens Market in the United States (2023-2034)
  • Figure 15: Smart Insulin Pens Market in Canada (2023-2034)
  • Figure 16: Smart Insulin Pens Market in Mexico (2023-2034)
  • Figure 17: Smart Insulin Pens Market in Europe (2023-2034)
  • Figure 18: Smart Insulin Pens Market in Germany (2023-2034)
  • Figure 19: Smart Insulin Pens Market in United Kingdom (2023-2034)
  • Figure 20: Smart Insulin Pens Market in France (2023-2034)
  • Figure 21: Smart Insulin Pens Market in Italy (2023-2034)
  • Figure 22: Smart Insulin Pens Market in Spain (2023-2034)
  • Figure 23: Smart Insulin Pens Market in the Rest of Europe (2023-2034)
  • Figure 24: Smart Insulin Pens Market in Asia-Pacific (2023-2034)
  • Figure 25: Smart Insulin Pens Market in China (2023-2034)
  • Figure 26: Smart Insulin Pens Market in Japan (2023-2034)
  • Figure 27: Smart Insulin Pens Market in India (2023-2034)
  • Figure 28: Smart Insulin Pens Market in Australia (2023-2034)
  • Figure 29: Smart Insulin Pens Market in South Korea (2023-2034)
  • Figure 30: Smart Insulin Pens Market in Rest of Asia-Pacific (2023-2034)
  • Figure 31: Smart Insulin Pens Market in the Rest of the World (2023-2034)
  • Figure 32: Smart Insulin Pens Market in the Middle East (2023-2034)
  • Figure 33: Smart Insulin Pens Market in Africa (2023-2034)
  • Figure 34: Smart Insulin Pens Market in South America (2023-2034)
  • Figure 35: Competitive Landscape
  • Figure 36: Startup Funding and Investment Trends